EXPRESSION OF IMMUNE MARKERS ALDH AND KRAS IN GASTRIC CANCER
Main Article Content
Abstract
Objectives: To desCribe the expression of immunohistoChemiCal markers ALDH and KRAS in gastriC CanCer. Methods: DesCriptiVe study, Cross- seCtional study design on 103 patients with a definitiVe diagnosis of gastriC CanCer and surgiCal remoVal of the tumor at K Hospital. EValuation of expression leVels of markers ALDH, KRAS in CanCer and Control samples. Results: The proportion of patients expressing ALDH at leVel 1+ aCCounted for 17.5%, leVel 2+ was 35.0% and 3+ aCCounted for 15.5%. The perCentage of patients with positiVe ALDH was 68.0%. The proportion of patients expressing KRAS at leVel 1+ aCCounts for 10.7%, leVel 2+ is 38.8% and 3+ aCCounts for 16.5%. The perCentage of patients with positiVe KRAS was 55.3%. There were 71.4% Cases of Co-expression of ALDH and KRAS. The rate of expression of a single marker was 27.2%. Two markers expressed simultaneously aCCounted for the highest rate with 48.5%. Conclusion: ImmunohistoChemiCal markers ALDH and KRAS Can be expressed alone or Co-expressed at a relatiVely high rate in gastriC CanCer patients.
Article Details
Keywords
ImmunohistoChemiCal markers ALDH, KRAS; immunohistoChemistry; gastriC CanCer
References

2. Wang L., Wang L., Yu Y., et al (2022). Aldehyde Dehydrogenase 1 in GastriC CanCer. J OnCol, 2022, 5734549.

3. Polom K., Das K., Marrelli D., et al (2019). KRAS Mutation in GastriC CanCer and PrognostiCation AssoCiated with MiCrosatellite Instability Status. Pathol OnCol Res, 25(1), 333-340.




4. Smyth E. C., Verheij M., Allum W., et al (2016). GastriC CanCer: ESMO CliniCal PraCtiCe Guidelines for diagnosis, treatment and follow-up. Ann OnCol, 27(suppl 5), V38-V49.

5. Võ Duy Long (2017). Đánh giá kết quả phẫu thuật nội sOi điều trị ung thư dạ dày theo giai đOạn I, II, III, Luận án Tiến sỹ y học, Trường Đại học Y DượC TP. Hồ Chí Minh.

6. Nguyễn Khắc Tấn (2023). Nghiên Cứu sự biểu lộ Và mối liên quan Của CáC dấu ấn miễn dịCh tế bào


gốc ung thư, HER2 trOng ung thư biểu mÔ tuyến dạ dày. Luận án Tiến sĩ y học, Trường Đại họC Y DượC Thái Nguyên.

7. Li X. S., Xu Q., Fu X. Y., et al (2014). ALDH1A1 oVerexpression is assoCiated with the progression and prognosis in gastriC CanCer. BMC CanCer, 14, 705.

8. Ayatollahi H., Tavassoli A., Jafarian A. H., et al (2018). KRAS Codon 12 and 13 Mutations in GastriC CanCer in the Northeast Iran. Iran J Pathol, 13(2), 167-172.
